| Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. | |
| | |
MedLine Citation:
|
PMID: 18579805 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Spinocerebellar ataxia type 15 (SCA15) is a progressive neurodegenerative disorder characterized by pure cerebellar ataxia, very slow progression, and distinct cerebellar atrophy. The locus for SCA15 was first mapped to 3p24.2-3pter in an Australian family. We have subsequently mapped two Japanese families presenting with ataxia and postural tremor of the head, arm, or trunk to the SCA15 locus. Recently, partial deletions involving both the type 1 inositol 1,4,5-triphosphate receptor (ITPR1) and sulfatase modifying factor 1 (SUMF1) genes have been identified in Australian and British families with SCA15. METHODS: We conducted fine haplotype analysis on the region including ITPR1. To identify the deletion, we conducted gene dosage analysis and array-based comparative genomic hybridization (aCGH) analysis. Gene expression analysis was performed using quantitative real-time reverse transcription PCR. Mutational analyses of ITPR1 and SUMF1 were also performed. RESULTS: We have identified a 414-kb deletion including the entire ITPR1 and exon 1 of SUMF1 in patients in family A. The expression levels of ITPR1 and SUMF1 mRNAs of the patient were half those of the normal control. Furthermore, in family B, we have identified a C-to-T substitution at position 8581 of ITPR1, resulting in the amino acid substitution of leucine for proline at codon 1059, which is highly conserved among species. CONCLUSIONS: Our results strongly confirm that ITPR1 is the causative gene for SCA15 and suggest that we need to investigate the point mutation in ITPR1 in the patients with autosomal dominant cerebellar ataxia and tremor. |
| | |
Authors:
|
K Hara; A Shiga; H Nozaki; J Mitsui; Y Takahashi; H Ishiguro; H Yomono; H Kurisaki; J Goto; T Ikeuchi; S Tsuji; M Nishizawa; O Onodera |
Related Documents
:
|
10970065 - Paroxysmal dyskinesias as a paradigm of paroxysmal movement disorders. 6438975 - Familial elevation of serum thyroxine binding globulin in an icelandic family. 7726165 - The severe perinatal form of autosomal recessive polycystic kidney disease maps to chro... 9193215 - Inherited nonsyndromic hearing loss. an audiovestibular study in a large family with au... 6608795 - Regional assignment of human amylase (amy) to p22----p21 of chromosome 1. 7287875 - Genetic and endocrine findings in a 31-year-old 45,x/46,xdel(y)(q12) male. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-06-25 |
Journal Detail:
|
Title: Neurology Volume: 71 ISSN: 1526-632X ISO Abbreviation: Neurology Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-08-19 Completed Date: 2008-10-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401060 Medline TA: Neurology Country: United States |
Other Details:
|
Languages: eng Pagination: 547-51 Citation Subset: AIM; IM |
Affiliation:
|
Department of Molecular Neuroscience, Center for Bioresource-based Researches, Brain Research Institute, Niigata University, 1-757, Asahi-machi-dori, Niigata City 951-8585, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Amino Acid Substitution / genetics Australia DNA Mutational Analysis Disease Progression Female Gene Deletion* Genes, Dominant Haplotypes Heterozygote Humans Inositol 1,4,5-Trisphosphate Receptors / genetics* Japan Male Middle Aged Mutation, Missense* Pedigree Point Mutation Sequence Deletion / genetics* Spinocerebellar Ataxias / genetics* Sulfatases / genetics* Tremor / genetics |
| Chemical | |
Reg. No./Substance:
|
0/ITPR1 protein, human; 0/Inositol 1,4,5-Trisphosphate Receptors; EC 3.1.6.-/SUMF1 protein, human; EC 3.1.6.-/Sulfatases |
| Comments/Corrections | |
Comment In:
|
Neurology. 2008 Aug 19;71(8):542-3
[PMID:
18711106
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia.
Next Document: Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.